HCG experience of modified FOLFIRINOX regimen in advanced pancreatic cancer

被引：0
|
作者：
Satheesh, Thungappa [1 ]
Shashidhara, P. [1 ]
Ravi, Thippeswamy [2 ]
Shekar, Patil [1 ]
机构：
[1] Hlth Care Global, Bangalore, Karnataka, India
[2] Sri Shankara Canc Res Ctr, Bangalore, Karnataka, India
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-218
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Impact of formulation on the iontophoretic delivery of the FOLFIRINOX regimen for the treatment of pancreatic cancer
    Byrne, James D.
    Jajja, Mohammad R. N.
    O'Neill, Adrian T.
    Schorzman, Allison N.
    Keeler, Amanda W.
    Luft, J. Christopher
    Zamboni, William C.
    DeSimone, Joseph M.
    Yeh, Jen Jen
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (06) : 991 - 998
  • [42] FOLFIRINOX in locally advanced and metastatic pancreatic cancer.
    Faris, Jason Edward
    Hong, Theodore S.
    McDermott, Shaunagh
    Borger, Darrell R.
    Guimaraes, Alexander R.
    Wo, Jennifer Yon-Li
    Sahani, Dushyant
    Dias, Lauren Elizabeth
    Allen, Jill N.
    Zhu, Andrew X.
    Murphy, Janet E.
    Kwak, Eunice Lee
    Ryan, David P.
    Clark, Jeffrey W.
    Blaszkowsky, Lawrence Scott
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [43] FOLFIRINOX: a new standard treatment for advanced pancreatic cancer?
    Kim, Richard
    LANCET ONCOLOGY, 2011, 12 (01): : 8 - 9
  • [44] Clinical outcomes for modified FOLFIRINOX chemotherapy for pancreatic cancer
    Holyoake, D.
    Lo, C.
    Stubbings, H.
    Roques, T.
    ANNALS OF ONCOLOGY, 2018, 29
  • [45] Modified FOLFIRINOX for resected pancreatic cancer: Opportunities and challenges
    Feng Yang
    Chen Jin
    De-Liang Fu
    Andrew L Warshaw
    World Journal of Gastroenterology, 2019, (23) : 2839 - 2845
  • [46] Modified FOLFIRINOX for resected pancreatic cancer: Opportunities and challenges
    Yang, Feng
    Jin, Chen
    Fu, De-Liang
    Warshaw, Andrew L.
    WORLD JOURNAL OF GASTROENTEROLOGY, 2019, 25 (23) : 2839 - 2845
  • [47] Impact of formulation on the iontophoretic delivery of the FOLFIRINOX regimen for the treatment of pancreatic cancer
    James D. Byrne
    Mohammad R. N. Jajja
    Adrian T. O’Neill
    Allison N. Schorzman
    Amanda W. Keeler
    J. Christopher Luft
    William C. Zamboni
    Joseph M. DeSimone
    Jen Jen Yeh
    Cancer Chemotherapy and Pharmacology, 2018, 81 : 991 - 998
  • [48] Operated Pancreatic Cancer: Modified FOLFIRINOX versus Gemcitabine
    Lorenz, Judith
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2019, 57 (03): : 290 - 290
  • [49] Phase II study of Yale modified FOLFIRINOX (mFOLFIRINOX) in locally advanced pancreatic cancer (LAPC).
    Stein, Stacey
    Cong, Xiangyu
    Yao, Xiaopan
    Hahn, Carol
    Li, Jia
    Kortmansky, Jeremy S.
    Chang, Bryan William
    Cha, Charles
    Salem, Ronald R.
    Hochster, Howard S.
    Lacy, Jill
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [50] Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer
    Stacey M Stein
    Edward S James
    Yanhong Deng
    Xiangyu Cong
    Jeremy S Kortmansky
    Jia Li
    Carol Staugaard
    Doddamane Indukala
    Ann Marie Boustani
    Vatsal Patel
    Charles H Cha
    Ronald R Salem
    Bryan Chang
    Howard S Hochster
    Jill Lacy
    British Journal of Cancer, 2016, 114 : 737 - 743
12345